Trump seeking economic deal with China as fresh trade talks loom- WSJ
Michael DePasquale, the Chief Executive Officer and Chairman of BIO-key International Inc. (NASDAQ:BKYI), recently purchased 4,000 shares of the company’s common stock. The transaction, which took place on June 3, 2025, was executed at a price of $0.83 per share, totaling $3,320. According to InvestingPro data, this purchase occurred as the company trades at a low revenue valuation multiple, with the stock down over 57% in the past year.
Following this acquisition, DePasquale’s direct ownership of BIO-key International stands at 48,519 shares. It is important to note that these holdings do not include options to purchase an additional 232 shares. This transaction underscores DePasquale’s continued investment in the company as he maintains his leadership roles. InvestingPro analysis reveals the company maintains impressive gross profit margins of 80% and holds more cash than debt on its balance sheet. For deeper insights into insider trading patterns and 11 additional ProTips, consider exploring the comprehensive Pro Research Report available on InvestingPro.
In other recent news, BIO-key International reported its Q1 2025 earnings with a revenue of $1.6 million, reflecting a 10% increase from the previous quarter but a decline from $2.2 million in the same period last year. The company faced a net loss of $737,000, equating to $0.16 per share, but improved its cash position to over $3 million. BIO-key also announced a strategic partnership with Runlevel, aiming to enhance cybersecurity in Portuguese-speaking African countries and Timor-Leste. This partnership’s first major deployment is with a National Bank in Mozambique, showcasing the demand for BIO-key’s Identity and Access Management solutions. Additionally, BIO-key’s strategic shift away from Swivel Secure licenses towards its branded offerings in EMEA is expected to drive future growth. The company’s focus on government sectors and biometric solutions is anticipated to support its growth trajectory. Analysts from Maxim Group have noted the potential for a $3 million renewal from BIO-key’s largest customer in Q1 2026, indicating confidence in the company’s long-term prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.